ICU Medical, Inc. — Q3 2015 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2015. ICU Medical develops, manufactures, and sells medical devices for infusion therapy, oncology, and critical care. Results are unaudited.
Financial performance and liquidity
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Total revenue | $86.0 million | $77.5 million | $251.3 million | $229.4 million |
| Gross profit / margin | $46.3 million / 54% | $38.1 million / 49% | $132.5 million / 53% | $111.7 million / 49% |
| Operating income | $24.8 million | $8.4 million | $56.1 million | $27.0 million |
| Net income | $16.3 million | $6.4 million | $39.5 million | $19.0 million |
| Diluted EPS | $0.98 | $0.42 | $2.41 | $1.22 |
| Operating cash flow | — | $42.4 million | $48.3 million |
Q3 revenue increased 11% year over year as reported; management cited 14% growth on a constant-currency basis. Nine-month reported revenue rose 10%, or 13% on a constant-currency basis. Infusion therapy and oncology drove growth; critical care was roughly flat for the nine-month period. Management attributed stronger gross margin primarily to favorable customer and product mix, operational efficiencies, and currency effects on operating costs.
At September 30, cash and cash equivalents were $355.4 million and investment securities were $38.7 million, totaling $394.1 million, up from $346.8 million at year-end 2014. Current assets were $513.7 million versus current liabilities of $37.2 million. The balance sheet reports no borrowings; long-term liabilities were $1.6 million. Shareholders’ equity was $567.2 million. Operating cash flow declined year over year, in part because receivables and prepaid expenses increased. Investing cash flow was $25.2 million, including net investment-security sales and building-sale proceeds; financing cash flow was $17.8 million.
Material changes and unusual items
- Q3 operating results included a $5.3 million net award from an arbitration with a service provider and a $1.1 million gain on sale of a building. The nine-month period also included a $7.1 million charge for the Hospira arbitration, producing $1.8 million of net legal-settlement expense year to date.
- Q3 restructuring and strategic-transaction expenses totaled $3.4 million, including $2.3 million of restructuring charges and $1.1 million related to a strategic transaction. The restructuring included a $1.8 million employment buyout with monthly payments through December 2020.
- On October 6, 2015, the company completed the acquisition of EXC Holding Corp. for $59.5 million cash and the sale of certain acquired product assets for $27.0 million cash.
- Foreign currency translation reduced nine-month comprehensive income; approximately 14% of nine-month revenue was denominated in euros.
Outlook, risks, and contingencies
Management estimated 2015 capital expenditures of approximately $10–$13 million and said existing cash, investments, and expected operating cash generation should fund operations for the next 12 months. It also stated that foreign-subsidiary cash of $31.9 million was expected to remain permanently invested abroad. No specific revenue or earnings guidance was provided.
Customer concentration is significant: Hospira represented 36% of revenue in both the quarter and nine-month period and 32% of receivables at quarter-end. The company’s Hospira distribution agreements extend through most of 2018. Management warned that adverse changes in this relationship, currency movements, competition and pricing pressure, product-development execution, regulation, and litigation outcomes could affect results. The filing says routine legal proceedings are not expected to materially harm financial position or results; indemnification agreements have no stated maximum, although management did not expect material liability. No material changes to previously disclosed risk factors were reported.
Key facts for investors to verify
- Whether revenue and margin growth persist after considering the favorable mix, operational, currency, and one-time settlement effects in 2015.
- Hospira’s ongoing revenue contribution, customer receivable exposure, and the status and terms of its distribution relationship.
- The EXC acquisition and asset-sale economics, integration costs, and expected contribution to results.
- Cash conversion and working-capital trends, particularly receivables and prepaid expenses, alongside planned capital spending and any share repurchases.
- Potential exposure to foreign exchange movements and the timing and cash impact of long-term restructuring payments.